文献速递中医内科中药与中成药合理使用

红景Ⅰ号颗粒治疗轻中度勃起功能障碍的随机对照试验

Efficacy of Hongjing I granule, an herbal medicine, in patients with mild to moderate erectile dysfunction in a randomized controlled trial.
PubMed 文献 · Front Pharmacol · 2024-12-24

多中心双盲随机安慰剂对照试验评估红景Ⅰ号颗粒治疗中医气虚血瘀型轻中度勃起功能障碍的疗效与安全性。随机后8周,红景Ⅰ号组IIEF-EF评分平均变化7.80(±3.25),安慰剂组3.33(±3.90),差异有统计学意义(P<0.001);两组均未报告不良事件。

要点

  • 红景Ⅰ号颗粒可显著改善气虚血瘀型轻中度ED患者的IIEF-EF评分。
  • SEP3中位变化两组差异有统计学意义(P=0.05),红景Ⅰ号组优于安慰剂。
  • 中医症状评分改善红景Ⅰ号组优于安慰剂,两组均未报告不良事件。

核心结论

  • 红景Ⅰ号颗粒显著改善轻中度勃起功能障碍患者的症状,但需进一步延长随机试验验证。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验,纳入中医气虚血瘀证轻中度ED患者。
  • 计划入组100例,随机分为红景Ⅰ号组(N=50)与安慰剂组(N=50),治疗8周。
  • 实际入组122例男性,基线IIEF-EF评分均值16.00[IQR:13.00,18.00]。
  • 主要结局为IIEF-EF评分、性交概况(SEP)及中医症状评分。

主要发现

  • 随机后8周,红景Ⅰ号组IIEF-EF评分平均变化7.80(±3.25),安慰剂组3.33(±3.90),差异有统计学意义(P<0.001)。
  • SEP3评分中位变化红景Ⅰ号组0.50[IQR:0.36,0.75],安慰剂组0.50[0.20,0.67],差异有统计学意义(P=0.05)。
  • 红景Ⅰ号组中医症状评分改善显著优于安慰剂组,两组均未报告不良事件。

关键数值与推荐

  • IIEF-EF评分变化:红景Ⅰ号组7.80(±3.25) vs 安慰剂组3.33(±3.90),P<0.001。
  • SEP3评分中位变化:红景Ⅰ号组0.50[0.36,0.75] vs 安慰剂组0.50[0.20,0.67],P=0.05。

临床怎么用

  • 对中医气虚血瘀证轻中度ED患者,可考虑红景Ⅰ号颗粒治疗8周以改善勃起功能。
  • 治疗期间关注IIEF-EF与SEP3评分变化及中医症状改善情况。

局限性

  • 研究入组对象为偏好纯中医治疗的患者,结果外推需谨慎。
  • 作者指出需进一步延长随机试验以验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HJIG is a potential treatment for erectile dysfunction (ED) that has been used in China for over 20 years. We conducted a multi-center, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of the Chinese Herbal Medicine, Hongjing I granule (HJIG), in patients with mild to moderate erectile dysfunction (ED). METHODS: This study is structured as a randomized, double-blind, placebo-controlled trial, executed across multiple centers. The recruitment strategy is primarily oriented towards patients demonstrating a pronounced preference for solely leveraging traditional Chinese medicine (TCM) interventions, a preference that is widely observed within TCM healthcare settings. A total of 100 patients, presenting with mild to moderate ED, specifically linked to the traditional diagnostic criteria of qi deficiency and blood stasis, will be enrolled. These participants will be randomly distributed between the HJIG (N = 50) and placebo (N = 50) arms. The designated treatment period is set at 8 weeks. Primary outcome measures encompass the International Index of Erectile Function-Erectile Function domain (IIEF-EF) score, the Sexual Encounter Profile (SEP), and scores derived from the traditional Chinese medicine symptom evaluation. RESULTS: Of the 122 men enrolled, the baseline IIEF-EF score averaged 16.00 [IQR: 13.00, 18.00]. Eight weeks post-randomization, the HJIG group demonstrated a mean change in IIEF-EF scores of 7.80 (±3.25), compared to 3.33 (±3.90) in the placebo group, signifying a marked difference (P < 0.001). The median alterations in SEP3 scores were 0.50 [IQR: 0.36, 0.75] for the HJIG group and 0.50 [0.20, 0.67] for the placebo group, revealing a statistically relevant distinction (P = 0.05). In both primary outcomes, HJIG proved superior to the placebo. Additionally, improvements in TCM symptom scores were notably greater in the HJIG group relative to the placebo, with no adverse events reported across both groups. CONCLUSION: The Hongjing I granule significantly improved symptoms in patients with mild to moderate ED. However, to validate these findings, further extended randomized trials are warranted. CLINICAL TRIAL REGISTRATION: The study has been registered in the Chinese Clinical Trial Registry (ChiCTR) and the registration number was ChiCTR2000041127.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xu RN, Guo J, Zhang CH, et al. Efficacy of Hongjing I granule, an herbal medicine, in patients with mild to moderate erectile dysfunction in a randomized controlled trial. Front Pharmacol. 2024. PMID: 39776582. doi:10.3389/fphar.2024.1367812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。